Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany

Ulrike Theidel, Christian Asseburg, Evangelos Giannitsis, Hugo Katus, Ulrike Theidel, Christian Asseburg, Evangelos Giannitsis, Hugo Katus

Abstract

The aim of this health economic analysis was to compare the cost-effectiveness of ticagrelor versus clopidogrel within the German health care system. A two-part decision model was adapted to compare treatment with ticagrelor or clopidogrel in a low-dose acetylsalicylic acid (ASA) cohort (≤150 mg) for all ACS patients and subtypes NSTEMI/IA and STEMI. A decision-tree approach was chosen for the first year after initial hospitalization based on trial observations from a subgroup of the PLATO study. Subsequent years were estimated by a Markov model. Following a macro-costing approach, costs were based on official tariffs and published literature. Extensive sensitivity analyses were performed to test the robustness of the model. One-year treatment with ticagrelor is associated with an estimated 0.1796 life-years gained (LYG) and gained 0.1570 quality-adjusted life-years (QALY), respectively, over the lifetime horizon. Overall average cost with ticagrelor is estimated to be EUR 11,815 vs. EUR 11,387 with generic clopidogrel over a lifetime horizon. The incremental cost-effectiveness ratio (ICER) was EUR 2,385 per LYG (EUR 2,728 per QALY). Comparing ticagrelor with Plavix(®) or the lowest priced generic clopidogrel, ICER ranges from dominant to EUR 3,118 per LYG (EUR 3,567 per QALY). These findings are robust under various additional sensitivity analyses. Hence, 12 months of ACS treatment using ticagrelor/ASA instead of clopidogrel/ASA may offer a cost-effective therapeutic option, even when the generic price for clopidogrel is employed.

Figures

Fig. 1
Fig. 1
Model structure used for all subgroup analyses
Fig. 2
Fig. 2
Results of univariate sensitivity analysis for overall ACS patient population ≤150 mg ASA
Fig. 3
Fig. 3
Results of the probabilistic sensitivity analysis
Fig. 4
Fig. 4
Cost-effectiveness acceptability curve

References

    1. Zeymer U, Zahn R, Gitt A, et al. Aktuelle Versorgungsstruktur der Therapie des akuten Herzinfarkts in Deutschland. Der Kardiologe. 2010;4(3):231–235. doi: 10.1007/s12181-010-0273-3.
    1. Robert Koch-Insitut (2006) Koronare Herzkrankheit und akuter Myokardinfarkt, Heft 33. . Accessed 5 Dec 2010
    1. AOK Bundesverband, FEISA, WidO (2007) Qualitätssicherung der stationären Versorgung mit Routinedaten (QSR) Abschlussbericht 2007. Wissenschaftliches Insitut der AOK, editor. . Accessed: 4 July 2011
    1. Damm K, Runge C, Zeymer U, et al. Krankheitskosten des akuten Koronarsyndroms in Deutschland. Der Kardiologe. 2011;5(2):122–128. doi: 10.1007/s12181-011-0328-0.
    1. Zobel C, Dorpinghaus M, Reuter H, et al. Mortality in a cardiac intensive care unit. Clin Res Cardiol. 2012;101(7):521–524. doi: 10.1007/s00392-012-0421-9.
    1. Peterson ED, Roe MT, Mulgund J, et al. Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA. 2006;295(16):1912–1920. doi: 10.1001/jama.295.16.1912.
    1. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. Eur Heart J. 2010;31(20):2501–2555. doi: 10.1093/eurheartj/ehq277.
    1. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057. doi: 10.1056/NEJMoa0904327.
    1. Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011;124(5):544–554. doi: 10.1161/CIRCULATIONAHA.111.047498.
    1. AstraZeneca (2011) Fachinformation Brilique, Stand: Oktober 2011. Rote Liste® Service GmbH, editor. . Accessed 28 June 2012
    1. Gemeinsamer Bundesausschuss (2011) Ticagrelor—Dossier zur Nutzenbewertung gemäß §35a SGB V: Modul 4 Kodierung. . Accessed 11 Apr 2011
    1. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (2011) Ticagrelor—Nutzenbewertung gemäß § 35a SGB V: Dossierbewertung; Auftrag: A11-02. . Accessed 24 Oct 2011
    1. Henriksson M, Nikolic E, Janzon M, Hauch O, Levin LA, Wallentin L, For the PLATO health economic substudy group (2011) Long-term costs and health outcomes of treating acute coronary syndrome patients with ticagrelor based on the EU label—Cost-effectiveness analysis based on the PLATO study. Value in Health
    1. Nikolic E, Janzon M, Hauch O, et al. Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. Eur Heart J. 2012
    1. Haeusler KG, Konieczny M, Endres M, et al. Impact of anticoagulation before stroke on stroke severity and long-term survival. Int J Stroke. 2011
    1. Gesundheitsberichterstattung des Bundes (2012) Diagnosedaten der Krankenhäuser ab 2000 (Fälle/Sterbefälle, Berechnungs- und Belegungstage, durchschnittliche Verweildauer). Gliederungsmerkmale: Jahre, Behandlungsort, Alter, Geschlecht, Verweildauer, ICD10. . Accessed 23 Oct 2011
    1. Taylor MJ, Scuffham PA, McCollam PL, et al. Acute coronary syndromes in Europe: 1-year costs and outcomes. Curr Med Res Opin. 2007;23(3):495–503. doi: 10.1185/030079906X167462.
    1. Gesundheitsberichterstattung des Bundes (2011) Krankheitskosten je Einwohner in €. Gliederungsmerkmale: Jahre, Deutschland, Alter, Geschlecht, ICD10, Einrichtungen. . Accessed 23 Oct 2011
    1. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (2009) Arbeitspapier Kostenbestimmung V1.0. . Accessed 11 Apr 2011
    1. Janzon M, Lundborg E, Henriksson M et al. (2010) Abstract 17295: Health Economics in the PLATelet inhibition and Patient Outcomes (PLATO) Randomized Trial: Report on Within Trial Resource Use Patterns. Circulation 122 (21_MeetingAbstracts): A17295
    1. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (2009) Arbeitspapier Modellierung V1.0. . Accessed 11 Apr 2011
    1. Nöthen M (2011) Hohe Kosten im Gesundheitswesen: Eine Frage des Alters? Statistisches Bundesamt, editor. . Accessed 11 Apr 2011
    1. Anonym (2012) Preismeldungen. LAUER-FISCHER GmbH, editor. . Accessed 29 June 2012
    1. Institut für das Entgeltsystem im Krankenhaus (2011) DRG Browser. . Accessed 05 Dec 2011
    1. Brüggenjürgen B, Rupprecht HJ, Willich SN. Cost of atherothrombotic diseases-myocardial infarction, ischaemic stroke and peripheral arterial occlusive disease-in Germany. J Public Health. 2005;13:216–224. doi: 10.1007/s10389-005-0112-3.
    1. Rossnagel K, Nolte CH, Müller-Nordhorn J, et al. Medical resource use and costs of health care after acute stroke in Germany. Eur J Neurol. 2005;12:862–868. doi: 10.1111/j.1468-1331.2005.01091.x.
    1. Zeidler J, Mittendorf T, Vahldiek G, et al. Kostenvergleichsanalyse der ambulanten und stationären kardiologischen Rehabilitation. Herz. 2008;33(440):447.
    1. Lamotte M, Annemanns L, Evers T, et al. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease. Pharmacoeconomics. 2006;24(2):155–169. doi: 10.2165/00019053-200624020-00005.
    1. Winter Y, Wolfram C, Schöffski O, et al. Langzeitkrankheitskosten 4 Jahre nach Schlaganfall oder TIA in Deutschland. Nervenarzt. 2008;79:918–926. doi: 10.1007/s00115-008-2505-3.
    1. Berger K, Hessel F, Kreuzer J, et al. Clopidogrel versus aspirin in patients with atherothrombosis: cAPRIE-based calculation of cost-effectiveness for Germany. Curr Med Res Opin. 2008;24(1):267–274.
    1. Gesundheitsberichterstattung des Bundes (2011) Arbeitsunfähigkeit bei AOK-Pflichtmitgliedern ohne Rentner (Arbeitsunfähigkeitsfälle, Arbeitsunfähigkeitsfälle je 100.000 Pflichtmitglieder, Arbeitsunfähigkeitstage, Arbeitsunfähigkeitstage je 100.000 Pflichtmitglieder,Tage je Fall). Gliederungsmerkmale: Jahre, Deutschland, Geschlecht, ICD-10. . Accessed 23 Oct 2011
    1. Schulenburg JM, Greiner W, Jost F, et al. Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation—dritte und aktualisierte Fassung des Hannoveraner Konsens. Gesundh ökon Qual manag. 2007;12:285–290. doi: 10.1055/s-2007-963505.
    1. Theidel U, Asseburg C, Giannitsis E, Katus H. Cost effectiveness of ticagrelor in the treatment of acute coronary syndrome (ACS) in Germany Abstract submitted to ISPOR 14th Annual European Congress. 2011
    1. Schöffski O, Schulenburg JM. Gesundheitsökonomische Evaluationen. 3. Berlin: Springer; 2007.
    1. Cohen M. Predictors of bleeding risk and long-term mortality in patients with acute coronary syndromes. Curr Med Res Opin. 2005;21(3):439–445. doi: 10.1185/030079905X30725.
    1. Stracke S, Dorr O, Heidt MC, et al. GRACE risk score as predictor of in-hospital mortality in patients with chest pain. Clin Res Cardiol. 2010;99(10):627–631. doi: 10.1007/s00392-010-0160-8.
    1. Fitchett D. The impact of bleeding in patients with acute coronary syndromes: how to optimize the benefits of treatment and minimize the risk. Can J Cardiol. 2007;23(8):663–671. doi: 10.1016/S0828-282X(07)70229-5.
    1. Bufe A, Frey S, Briswalter S (2009) Durch Blutungen verursachte Kosten bei der Therapie des akuten Koronarsyndroms in Deutschland. Herz 479; 484
    1. Kolominsky-Rabas PL, Heuschmann PU, Marschall D, et al. Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project. Stroke. 2006;37(5):1179–1183. doi: 10.1161/01.STR.0000217450.21310.90.
    1. Schweikert B, Hunger M, Meisinger C, et al. Quality of life several years after myocardial infarction: comparing the MONICA/KORA registry to the general population. Eur Heart J. 2009;30(4):436–443. doi: 10.1093/eurheartj/ehn509.
    1. AstraZeneca. PLATO—A Study of PLATelet inhibition and Patient Outcomes (clinical study report). [unveröffentlicht] 2009
    1. Dyer MTD, Goldsmith KA, Sharples LS et al. (2010) Are view of health utilities using the EQ-5D in studies of cardiovascular disease. Health Qual Life Out 8: 13
    1. Wiesner G, Grimm J, Bittner E. Vorausberechnungen des Herzinfarktgeschehens in Deutschland. Bundesgesundheitsblatt. 2002;45:438–445. doi: 10.1007/s00103-002-0405-4.
    1. Hamm CW. Leitlinien: Akutes Koronarsyndrom (ACS), Teil 2. Z Kardiol. 2004;93:324–341. doi: 10.1007/s00392-004-0109-x.
    1. Hamm CW. Leitlinien: Akutes Koronarsyndrom (ACS), Teil 1. Z Kardiol. 2004;93:72–90. doi: 10.1007/s00392-004-1064-2.
    1. Anonym (2010) Threshold values for intervention cost-effectiveness by Region. Accessed 23 Oct 2010
    1. Barbieri M, Drummond M, Willke R, et al. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health. 2005;8(1):10–23. doi: 10.1111/j.1524-4733.2005.03070.x.
    1. AstraZeneca. EMEA/H/C/1241: Ticagrelor Tablets Additional PLATO subgroup analysis on overall PLATO UA/NSTEMI and STEMI subgroups and ASA Γëñ150 mg cohort for the German Value Dossier. 2011

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren